- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07730970
Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES Hysterectomy (vNOTES_NMBDIET)
Effect of Deep Neuromuscular Blockade and a Preoperative Low-Residue Diet on Intra-operative Surgical Field Conditions During Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) Hysterectomy: A 2×2 Factorial, Assessor-Blinded Randomized Controlled Trial
vNOTES (vaginal natural orifice transluminal endoscopic surgery) hysterectomy is performed entirely through the vagina, with no abdominal incision. A clear surgical view is essential, and the main obstacle to the view is bowel falling into the pelvis. This randomized trial tests whether two simple measures improve the surgical field, individually or in combination: a preoperative low-residue diet for three days, and deeper intra-operative muscle relaxation (deep neuromuscular blockade). No group receives mechanical bowel preparation.
Using a 2×2 factorial design, participants are allocated equally (1:1:1:1) to one of four groups: (1) no diet with standard relaxation; (2) diet with standard relaxation; (3) no diet with deep relaxation; (4) diet with deep relaxation (the "bundle"). The surgical field is measured objectively: during a standardized window the carbon-dioxide insufflation pressure is lowered step by step, and 2-3 blinded assessors score the field from de-identified video. The primary outcome is the lowest pressure at which the field remains adequate; a lower pressure indicates an intrinsically better field.
The trial hypothesis is an interaction - that the combination achieves an adequate field at a meaningfully lower pressure than either measure alone. The final sample size is determined from an internal pilot. Secondary outcomes include the continuous field score, the need for an additional instrument to clear the field, postoperative nausea and vomiting, and routine operative outcomes.
연구 개요
상태
상세 설명
The field is scored with the vNOTES-OVI, a 3-point index (0 = inadequate, 1 = adequate only with instrument bowel-retraction, 2 = optimal/clear), adapted for vNOTES from the team's prior objective visualisation index in conventional laparoscopy. At each 1 mmHg step a 3-second clip is recorded with a fixed scanning choreography (right adnexa → midline/cephalic boundary → left adnexa); the consensus (median) of the blinded assessors defines, per participant, the lowest pressure at which the field is adequate (OVI ≥ 1; primary) and at which it is optimal (OVI = 2; secondary).
Deep relaxation is rocuronium by continuous infusion to a post-tetanic count of 1-2 (no train-of-four twitches); standard relaxation is rocuronium by intermittent bolus to a train-of-four count of 1-2. Relaxation depth is monitored quantitatively and fully reversed (train-of-four ratio ≥ 0.9 confirmed) before extubation in every participant; the reversal agent is sugammadex in all four groups (neostigmine is not used), and because sugammadex dosing follows block depth (≈ 2 mg/kg moderate, ≈ 4 mg/kg deep) the dose differs by the NMB factor by necessity, so it is recorded per participant and reported by arm (collinear with NMB depth, it is examined only in a sensitivity analysis, not added as a covariate to the factorial nausea model). The step-down field measurement descends from 12 mmHg to 6 mmHg in 1 mmHg steps with a 60-second equilibration at each step. The preoperative low-residue diet (diet arms) restricts daily intake to less than 10 g of dietary fibre for the three days before surgery - permitting refined grains, well-cooked or canned skinless and seedless vegetables, peeled or canned fruit, tender meat, fish, eggs, and moderate dairy, while avoiding whole grains, raw fruits and vegetables, legumes, nuts, seeds, and dried fruit - and participants receive a written diet information sheet; no group receives mechanical bowel preparation. The primary outcome is assessor-blinded (assessors score de-identified video with pressure and group removed); the operating surgeon is blinded to allocation and the data analyst analyses with groups coded; the anaesthesia team is necessarily unblinded to relaxation depth but does not score the outcome. The internal pilot (≈ 10-15 per group) is used for blinded sample-size re-estimation; detecting an interaction typically requires several times the sample size of a main effect.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: MURAT Y Murat Yassa, MD (Assoc. Prof.) - Principal Investigator, ASSOCIATE PROFESSOR IN OBS GYN
- 전화번호: +905335106312
- 이메일: murat.yassa@acibadem.com
연구 장소
-
-
KARTAL
-
Istanbul, KARTAL, 터키 (Türkiye), 34865
- 모집하지 않고 적극적으로
- Kartal Dr. Lütfi Kırdar Şehir Hastanesi
-
Istanbul, KARTAL, 터키 (Türkiye)
- 모병
- Acibadem Kartal Hospital
-
연락하다:
- MURAT Y Murat Yassa, MD - Principal Investigator, MD, Assoc. Prof.
- 전화번호: +905335106312
- 이메일: murat.yassa@acibadem.com
-
-
Kütahya
-
Kütahya, Kütahya, 터키 (Türkiye), 43100
- 모집하지 않고 적극적으로
- Kütahya Şehir Hastanesi
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Adult women (aged 18 years or older) scheduled for hysterectomy for a benign (non-cancer) indication.
- Judged suitable for the vNOTES approach by the operating surgeon.
- Able to understand the study and provide written informed consent.
Exclusion Criteria:
- Suspected or known gynaecological malignancy.
- Conditions expected to make the approach or the field assessment non-standard (e.g., anticipated dense pelvic adhesions or severe endometriosis, a contraindication to vNOTES, or an obliterated cul-de-sac).
- Any medical reason why deep neuromuscular blockade or sugammadex would be unsafe (defined with the anaesthesia team).
- Any medical reason why a low-residue diet would be unsuitable.
- Inability to give informed consent.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm 2 - Diet + standard NMB
Three-day preoperative low-residue diet with standard (moderate) neuromuscular blockade.
No mechanical bowel preparation.
|
Rocuronium by intermittent bolus to maintain a train-of-four count of 1-2 (usual care); reversed with sugammadex and confirmation of full recovery (train-of-four ratio ≥ 0.9) before extubation. Cross-reference to arms: Arms 1, 2 A low-residue diet (less than 10 g dietary fibre per day) for the three days before surgery, with standardised food lists and a patient information sheet. This is a dietary measure, not a laxative; no mechanical bowel preparation is used. Cross-reference to arms: Arms 2, 4 |
|
실험적: Arm 3 - Deep NMB (no diet)
Deep neuromuscular blockade (post-tetanic count 1-2, continuous infusion) with no dietary restriction.
No mechanical bowel preparation.
|
Rocuronium by continuous infusion to maintain profound relaxation (no train-of-four twitches; post-tetanic count 1-2) until the end of the field measurement and surgery; reversed with sugammadex and confirmation of full recovery (train-of-four ratio ≥ 0.9) before extubation. Cross-reference to arms: Arms 3, 4 |
|
실험적: Arm 4 - Bundle (diet + deep NMB)
Three-day low-residue diet AND deep neuromuscular blockade - the combination of interest.
No mechanical bowel preparation.
|
A low-residue diet (less than 10 g dietary fibre per day) for the three days before surgery, with standardised food lists and a patient information sheet. This is a dietary measure, not a laxative; no mechanical bowel preparation is used. Cross-reference to arms: Arms 2, 4 Rocuronium by continuous infusion to maintain profound relaxation (no train-of-four twitches; post-tetanic count 1-2) until the end of the field measurement and surgery; reversed with sugammadex and confirmation of full recovery (train-of-four ratio ≥ 0.9) before extubation. Cross-reference to arms: Arms 3, 4 |
|
활성 비교기: Arm 1 - Control (no diet + standard neuromuscular blockade NMB)
Usual care: standard (moderate) neuromuscular blockade (train-of-four 1-2, intermittent bolus) and no dietary restriction.
No mechanical bowel preparation.
|
Rocuronium by intermittent bolus to maintain a train-of-four count of 1-2 (usual care); reversed with sugammadex and confirmation of full recovery (train-of-four ratio ≥ 0.9) before extubation. Cross-reference to arms: Arms 1, 2 |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lowest CO₂ insufflation pressure at which the surgical field is adequate (blinded Transvaginal Natural Orifice Endoluminal Surgery - Objectiveisual Index: vNOTES-OVI ≥ 1)
기간: Intra-operative (single measurement window)
|
During a standardized intra-operative window, insufflation pressure is lowered from 12 mmHg to 6 mmHg in 1 mmHg steps, with a 60-second equilibration at each step; at each step a 3-second de-identified video clip is scored by 2-3 blinded assessors with the vNOTES-OVI (0/1/2).
The consensus (median) score yields, per participant, the lowest pressure at which the field is adequate (OVI ≥ 1).
Lower pressure indicates a better field.
|
Intra-operative (single measurement window)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Continuous surgical-field score (vNOTES-OVI)
기간: Intra-operative
|
Blinded vNOTES-OVI (0/1/2) at each insufflation-pressure step, analysed as a threshold-free ordinal/continuous measure.
|
Intra-operative
|
|
Lowest pressure at the strict threshold (vNOTES-OVI = 2)
기간: Intra-operative
|
Lowest insufflation pressure at which the field is perfectly exposed (OVI = 2), blinded scoring.
|
Intra-operative
|
|
Requirement for a third working instrument
기간: Intra-operative
|
Whether an instrument beyond the camera and the two standard working instruments - introduced through the platform's existing channel, not a new abdominal port - was required solely to expose the field or displace bowel (yes/no per case).
|
Intra-operative
|
|
Postoperative nausea and vomiting - complete response
기간: 0-24 hours postoperative
|
Proportion of participants with no nausea AND no vomiting AND no rescue antiemetic during the first 24 hours.
|
0-24 hours postoperative
|
|
Nausea severity
기간: 0-24 hours postoperative
|
Worst nausea severity on a 4-point verbal scale (none/mild/moderate/severe), assessed by a blinded assessor at 0-2, 2-6, and 6-24 hours.
|
0-24 hours postoperative
|
|
Vomiting episodes
기간: 0-24 hours postoperative
|
Number of vomiting/retching episodes during the first 24 hours.
|
0-24 hours postoperative
|
|
Operative time
기간: Through surgery completion
|
Skin-to-skin operating time.
|
Through surgery completion
|
|
Estimated blood loss
기간: Through surgery completion
|
Estimated intra-operative blood loss (mL).
|
Through surgery completion
|
|
Conversion to another approach
기간: Intra-operative
|
Conversion to conventional laparoscopy or laparotomy (yes/no).
|
Intra-operative
|
|
Intra-operative and early postoperative complications
기간: hrough 24 hours postoperative
|
Complications recorded as counts by group.
|
hrough 24 hours postoperative
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Yassa M, Kaya C, Kalafat E, Tekin AB, Karakas S, Mutlu MA, Birol P, Tug N. The Comparison of Transvaginal Natural Orifice Transluminal Endoscopic Surgery and Conventional Laparoscopy in Opportunistic Bilateral Salpingectomy for Permanent Female Sterilization. J Minim Invasive Gynecol. 2022 Feb;29(2):257-264.e1. doi: 10.1016/j.jmig.2021.08.009. Epub 2021 Aug 16.
- Yassa M, Karadeniz O, Kaya C, Doğan O, Şentürk B, Çalışkan E. Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) Hysterectomy in Benign Gynecologic Indications: Evidence-Based Recommendations of the Pelvic Floor and Cosmetic Gynecology (PETKOZ) Association, Combined with Expert Consensus - A National Guideline. Anat J Obstet Gynecol Res. 2026 May 13;3(1):1-20. doi: 10.4274/anajog.galenos.2026.06078. Epub 2026 May 8.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- ATADEK 2026/12, 2026-12/513
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .